We are Glytego
Glytego Therapeutics Ltd. is an early-stage drug company whose mission
is to provide best-in-class precision therapeutics to alleviate
suffering caused by Inflammatory Bowel Disease.
Leadership
PhD
Founder, Co-Director
Dr. Harry Brumer is a Professor in the Michael Smith Laboratories and Department of Chemistry at the University of British Columbia. Dr. Brumer is an internationally recognized expert in carbohydrate enzymology and carbohydrate chemistry. Dr. Brumer's impactful research on the molecular mechanisms of dietary fibre metabolism by the human gut microbiota inspired the development of Glytego's GlycoCage Technology.
PhD
Founder, Co-Director
Dr. Laura Sly is a Professor in the Division of Gastroenterology, Department of Pediatrics, Faculty of Medicine at the University of British Columbia, and an Investigator at the BC Children's Hospital Research Institute. Dr. Laura Sly is a distinguished scientist, widely recognized for her leadership in immunology, gastroenterology, and translational research. Her research focuses on inflammatory bowel disease (IBD), regulatory T cells, and microbiome-driven therapies. A fellow of the Canadian Association of Gastroenterology, Dr. Sly continues to influence policy, mentorship, and advocacy while advancing groundbreaking solutions in IBD therapy, including Glytego's GlycoCage Technology.
Advisory Board
PhD
Advisor
Dr. Robert N. Ben is a Professor in the Department of Chemistry and Biomolecular Sciences at the University of Ottawa and the Canadian inventor of a pioneering class of small-molecule ice recrystallization inhibitors (IRIs). Dr. Ben built an interdisciplinary program spanning chemistry, cryobiology, blood products, stem cells, tissues and cellular therapies, and served as Director of uOttawa's Biopharmaceutical Sciences Program and Biomedical Sciences Programs for over a decade. In 2017, he co-founded PanTHERA CryoSolutions to translate his patented IRI technology into commercial products for cell and gene therapy applications. PanTHERA secured major investment and a co-development relationship with BioLife Solutions and Casdin Life Sciences, launched the GMP-compliant KryoAegis product in 2024, and was acquired by BioLife Solutions in 2025. Dr. Ben's career uniquely combines sustained academic leadership with successful entrepreneurship and industrial translation.
MD, FRCPC
Advisor
Dr. Remo Panaccione is a distinguished Professor of Medicine and the Director of the Inflammatory Bowel Disease (IBD) Unit at the University of Calgary. He also serves as the Dean of MD Admissions and directs the university’s IBD Fellowship Program. Dr. Panaccione holds the prestigious Crohn’s and Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease. His research interests lies in the design, implementation, and interpretation of clinical trials in IBD and has published over 500 peer-reviewed articles including in NEJM, Lancet, Nature, Gastroenterology and Gut. He has been recognized as a Clarivate Research Scholar, placing him in the top 1% of the world’s most-cited researchers. A dedicated clinician, educator, and researcher, Dr. Panaccione has received numerous honors, including recognition as a Canadian Association of Gastroenterology Visiting Professor, the 2020 Crohn’s and Colitis Canada Outstanding Physician of the Year, and the 2024 Research Leadership Award.
PhD
Advisor
Dr. David Vocadlo is a Professor at Simon Fraser University (SFU) in the Departments of Chemistry and Molecular Biology & Biochemistry and Distinguished University Professor in Chemical Biology. At SFU, Dr. Vocadlo leads a research team focused on developing chemical biology tools to illuminate disease biology. He is an inventor on over 30 families of patents and several technologies have been out-licensed from his SFU laboratory. His team pioneered the creation and preclinical validation of OGA inhibitors for neurodegenerative diseases, a strategy now advanced into clinical trials. Dr. Vocadlo and his team have been recognized with various awards including the EWR Steacie Memorial Fellowship, the Horace Isbell Award of the American Chemical Society. Dr. Vocadlo was recently appointed as a Fellow of the Royal Society of Canada. He is a serial entrepreneur, serving as CSO at Alectos Therapeutics and co-founded Carbaform Biosciences and Alectos Therapeutics, both of which have concluded licenses and advanced technologies with major multinational partners.